» » Aducanumab Approval, Part 2Healthy Care Renewal
Edit

Aducanumab Approval, Part 2Healthy Care Renewal

So how did a drug with such dubious benefit get approved? At best, another clinical trial might be warranted, but certainly not approval. It's a result of a huge campaign by a company (Biogen) that would not accept the failure of its drug and of pressure from patient organizations like the Alzheimer's Association (which receives major money from pharma, including Biogen and its Japanese partner,

from Health Care Renewal https://ift.tt/2UcJUJ9 Aducanumab Approval, Part 2Healthy Care Renewal

Subscribe to receive free email updates:

0 Response to "Aducanumab Approval, Part 2Healthy Care Renewal"

Post a Comment

Subscribe to: Post Comments (Atom)